The Clinical Implementation of Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry
| Autor: | Jaouad Azzahhafi MD, Wout W. A. van den Broek MD, Dean R. P. P. Chan Pin Yin MD, Ankie M. Harmsze PharmD, PhD, Ron H. N. van Schaik MSc, PhD, Jurriën M. ten Berg MD, PhD |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of Cardiovascular Pharmacology and Therapeutics, Vol 28 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1940-4034 10742484 |
| DOI: | 10.1177/10742484231210704 |
| Popis: | Background Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome (ACS) patients. However, these P2Y 12 inhibitors increase bleeding risk compared to clopidogrel. Although genotype-guided P2Y 12 -inhibitor selection has been shown to reduce bleeding risk, data on its clinical implementation is lacking. Methods The study included ACS patients receiving genotype-guided antiplatelet therapy, utilising either a point-of-care (POC) device or laboratory-based testing. We aimed to collect qualitative and quantitative data on genotyping, eligibility for de-escalation, physician adherence to genotype results, time to de-escalation and cost reduction. Results Of the 1,530 patients included in the ACS registry from 2021 to 2023, 738 ACS patients treated with ticagrelor received a CYP2C19 genotype test. The median turnover time of genotyping was 6.3 hours (interquartile range [IQR], 3.2-16.7), with 82.3% of the genotyping results known within 24 hours after admission. POC genotyping exhibited significantly shorter turnaround times compared to laboratory-based testing (with respective medians of 5.7 vs 47.8 hours; P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|